Lipella Pharmaceuticals Co-Founder Michael Chancellor Featured on the Pharmaverse Podcast

Episode titled "From Medicine to Biotech Innovation" now available

/EIN News/ -- PITTSBURGH, March 31, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us,” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet needs, today announced that Co-Founder and Chief Medical Officer Dr. Michael Chancellor is featured in the latest episode of The Pharmaverse Podcast, hosted by pharmaceutical industry executive recruiter Michael Pietrack.

The episode, titled “From Medicine to Biotech Innovation,” offers an inside look at Dr. Chancellor’s journey from clinical medicine to biotech leadership. In this candid conversation, he discusses how Lipella’s innovation was born out of unmet medical need, the complexities of navigating early-stage biotech, the challenges of clinical trials and fundraising, and the process of taking a company public.

Dr. Chancellor also shares leadership insights drawn from his 40-year career in medicine and drug development.

The Pharmaverse Podcast is a leadership-focused series that offers exclusive insights from executives across the pharmaceutical and biotech industries. Each episode features prominent voices sharing perspectives on career growth, industry trends, and leadership strategies.

Watch the episode: Pharmaverse Podcast – From Medicine to Biotech Innovation

In February 2025, Lipella reported positive topline Phase 2a results for its lead product candidate LP-310 in the treatment of Oral Lichen Planus. LP-310 demonstrated clinically meaningful reductions in pain, ulceration, and inflammation across all key metrics, reinforcing the Company’s commitment to addressing unmet needs in inflammatory mucosal diseases.

About Lipella Pharmaceuticals Inc. 
Lipella Pharmaceuticals is a clinical-stage biotechnology company focused on developing new drugs by reformulating active agents in existing generic drugs and optimizing these reformulations for new applications. Lipella targets diseases with significant unmet needs, where no approved drug therapies currently exist. The company completed its initial public offering in 2022. Learn more at lipella.com and follow us on X and LinkedIn .

Forward-Looking Statements 
This press release includes certain "forward-looking statements" which are not historical facts, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical fact, included in this press release regarding, among other things, our strategy, future operations, financial position, prospects, clinical trials, regulatory approvals, pipeline and opportunities, sources of growth, successful implementation of our proprietary technology, plans and objectives are forward-looking statements. Forward-looking statements can be identified by words such as "may," "will," "could," "continue," "would," "should," "potential," "target," "goal," "anticipates," "intends," "plans," "seeks," "believes," "estimates," "predicts," "expects," "projects" and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding future events and financial trends that we believe may affect among other things, market and other conditions, our financial condition, results of operations, business strategy, short- and long-term business operations and objectives, and financial needs. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. We caution you, therefore, against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. There are risks, uncertainties and other factors, both known and unknown, that could cause actual results to differ materially from those in the forward-looking statements which include, but are not limited to, the current clinical trial results for LP-310 and our other products general capital market risks, our ability to regain and maintain compliance with the listing standards of The Nasdaq Stock Market LLC, regional, national or global political, economic, business, competitive, market and regulatory conditions, our current liquidity position and the need to obtain additional financing to support ongoing operations, and other risks as more fully described in our filings with the U.S. Securities and Exchange Commission. Any forward-looking statement made by us is based upon the reasonable judgment of our management at the time such statement is made and speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law. Nothing contained herein is, or shall be relied upon as, a promise or representation as to the past or future. In addition, the information contained in this press release is as of the date hereof, and the Company has no obligation to update such information, including in the event that such information becomes inaccurate. You should not construe the contents of this press release as legal, tax or investment advice and should consult with your own advisors as to the matters described herein, as applicable.

CONTACT 
Jonathan Kaufman 
Chief Executive Officer 
Lipella Pharmaceuticals Inc. 
Info@Lipella.com 
1-412-894-1853

PCG Advisory 
Jeff Ramson 
jramson@pcgadvisory.com